CenterBook Partners LP Makes New Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

CenterBook Partners LP bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 4,283 shares of the company's stock, valued at approximately $671,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Entropy Technologies LP purchased a new stake in Krystal Biotech during the fourth quarter worth approximately $548,000. Janney Montgomery Scott LLC boosted its stake in shares of Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after buying an additional 15,545 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after purchasing an additional 3,727 shares during the period. abrdn plc increased its stake in shares of Krystal Biotech by 32.5% during the fourth quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after acquiring an additional 13,979 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Trading Up 1.1 %

NASDAQ KRYS traded up $1.88 during trading hours on Thursday, reaching $166.58. 61,890 shares of the company traded hands, compared to its average volume of 294,682. The stock has a market capitalization of $4.81 billion, a PE ratio of 55.88 and a beta of 0.75. The company has a 50 day moving average of $174.45 and a two-hundred day moving average of $172.08. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the company earned $0.30 earnings per share. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on KRYS shares. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Krystal Biotech presently has an average rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).